What the company does
Vivozon Pharmaceutical makes finished medicines, including treatments for circulatory conditions, diabetes, fever and pain relief, skin conditions, and influenza, supplied to patients through prescription and over-the-counter channels in Korea.
It is listed on KOSDAQ, Korea's tech and small-cap exchange. Beyond its own branded products, the company also operates contract manufacturing and private-label production businesses, giving it multiple revenue streams across its portfolio of well over a hundred product lines.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue · FY2025
US$43M
▼ −32.3% YoY
Operating profit · FY2025
−US$13.9M
Turned to loss
Net income · FY2025
−US$23.5M
Loss widened
Revenue
- FY2023US$51.7M
- FY2024US$63.5M
- FY2025US$43M
Operating profit
- FY2023US$1.9M
- FY2024US$2.1M
- FY2025−US$13.9M
Net income
- FY2023−US$2.4M
- FY2024−US$7.2M
- FY2025−US$23.5M
Key ratios (FY2025)
ROE
-44.6%
Debt/Eq
127.7%
Op. margin
-32.3%
Net margin
-54.6%
Rev. YoY
▼ −32.3%
Price charts coming soon
Interactive price history isn't here yet. Would you use it?